24/7 Market News Snapshot 04 March, 2025 – Stem, Inc. (NYSE:STEM)

March 4, 2025

DENVER, Colo., 04 March, 2025 (247marketnews.com) – (NYSE:STEM) are discussed in this article.
Stem, Inc. has made a significant impact in today’s trading session, beginning with a strong opening at $0.404 and rapidly climbing by 28.99% to a current value of $0.516. This notable ascent reflects heightened investor confidence and keen market interest, evidenced by a trading volume of 9.01 million shares. As the momentum builds, traders are advised to closely monitor critical support and resistance levels to make the most of this opportunity. The critical question remains whether Stem can sustain its upward trend.

In a parallel development, InfuSystem Holdings, Inc. has reported robust financial results for the fourth quarter and full year of 2024, underscoring its commitment to operational excellence. The company achieved net revenues of $33.8 million in the fourth quarter, marking a 7% increase from the prior year, largely attributed to a successful Patient Services segment, which generated $20.8 million—a year-over-year rise of 8%.

In addition to revenue growth, InfuSystem’s operating income surged by an impressive 109% to $2.6 million, highlighting effective margin management. The gross profit stood at $18.2 million, resulting in a gross margin of 53.8%, which improved by 1.2% compared to the previous year. Adjusted EBITDA for the quarter reached $7.5 million, representing a 22% year-over-year increase and a healthy margin of 22.2%.

Over the full year, InfuSystem realized net revenues of $134.9 million, also reflecting a 7% increase, underpinned by advancements in both its Patient Services and Device Solutions segments. A significant improvement in net income to $2.3 million from $0.8 million in the previous year further emphasizes the company’s financial health.

Management credits strategic initiatives, including a distribution agreement with Smith+Nephew, for laying a robust groundwork for ongoing growth. Looking toward 2025, the company projects revenue growth of 8% to 10% while continuing to enhance its Adjusted EBITDA margins, reaffirming its dedication to delivering high-quality healthcare solutions and maximizing shareholder value.

Related news for (STEM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.